Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM).
Functional MRI
Future liver remnant
Gadoxetate
Indocyanine green
Post hepatectomy liver failure
Risk assessment
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
23 Oct 2021
23 Oct 2021
Historique:
received:
28
02
2021
accepted:
04
10
2021
entrez:
24
10
2021
pubmed:
25
10
2021
medline:
12
2
2022
Statut:
epublish
Résumé
Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate. The Hepatectomy risk assessment with functional magnetic resonance imaging trial (HEPARIM) aims to establish if quantitative MRI biomarkers of liver function & perfusion can be used to more accurately predict PHLF risk and FLR function, measured against indocyanine green (ICG) liver function test. HEPARIM is an observational cohort study recruiting patients undergoing liver resection of 2 segments or more, prior to surgery patients will have both Dynamic Gadoxetate-enhanced (DGE) liver MRI and ICG testing. Day one post op ICG testing is repeated and R15 compared to the Gadoxetate Clearance (GC) of the future liver remnant (FLR-GC) as measure by preoperative DGE- MRI which is the primary outcome, and preoperative ICG R15 compared to GC of whole liver (WL-GC) as a secondary outcome. Data will be collected from medical records, biochemistry, pathology and radiology reports and used in a multi-variate analysis to the value of functional MRI and derive multivariant prediction models for future validation. If successful, this test will potentially provide an efficient means to quantitatively assess FLR function and PHLF risk enabling surgeons to push boundaries of liver surgery further while maintaining safe practice and thereby offering chance of cure to patients who would previously been deemed inoperable. MRI has the added benefit of already being part of the routine diagnostic pathway and as such would have limited additional burden on patients time or cost to health care systems. (Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging - Full Text View - ClinicalTrials.gov , n.d.) TRIAL REGISTRATION: ClinicalTrials.gov, ClinicalTrials.gov NCT04705194 - Registered 12th January 2021 - Retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate. The Hepatectomy risk assessment with functional magnetic resonance imaging trial (HEPARIM) aims to establish if quantitative MRI biomarkers of liver function & perfusion can be used to more accurately predict PHLF risk and FLR function, measured against indocyanine green (ICG) liver function test.
METHODS
METHODS
HEPARIM is an observational cohort study recruiting patients undergoing liver resection of 2 segments or more, prior to surgery patients will have both Dynamic Gadoxetate-enhanced (DGE) liver MRI and ICG testing. Day one post op ICG testing is repeated and R15 compared to the Gadoxetate Clearance (GC) of the future liver remnant (FLR-GC) as measure by preoperative DGE- MRI which is the primary outcome, and preoperative ICG R15 compared to GC of whole liver (WL-GC) as a secondary outcome. Data will be collected from medical records, biochemistry, pathology and radiology reports and used in a multi-variate analysis to the value of functional MRI and derive multivariant prediction models for future validation.
DISCUSSION
CONCLUSIONS
If successful, this test will potentially provide an efficient means to quantitatively assess FLR function and PHLF risk enabling surgeons to push boundaries of liver surgery further while maintaining safe practice and thereby offering chance of cure to patients who would previously been deemed inoperable. MRI has the added benefit of already being part of the routine diagnostic pathway and as such would have limited additional burden on patients time or cost to health care systems. (Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging - Full Text View - ClinicalTrials.gov , n.d.) TRIAL REGISTRATION: ClinicalTrials.gov, ClinicalTrials.gov NCT04705194 - Registered 12th January 2021 - Retrospectively registered.
Identifiants
pubmed: 34688256
doi: 10.1186/s12885-021-08830-4
pii: 10.1186/s12885-021-08830-4
pmc: PMC8541801
doi:
Banques de données
ClinicalTrials.gov
['NCT04705194']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1139Subventions
Organisme : Medical Research Council
ID : MR/P023398/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P023398/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : Grant Ref: MR/P023398/1
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
HPB (Oxford). 2019 Jul;21(7):912-922
pubmed: 30733048
Ann Surg. 2009 Jan;249(1):124-8
pubmed: 19106687
J Hepatol. 2016 Dec;65(6):1155-1162
pubmed: 27476767
J Nucl Med. 2010 Feb;51(2):229-36
pubmed: 20080899
JAMA Surg. 2013 Apr;148(4):385-91
pubmed: 23715907
World J Surg. 2016 Jun;40(6):1440-7
pubmed: 26902630
Br J Surg. 2011 Jun;98(6):836-44
pubmed: 21456090
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
HPB (Oxford). 2016 Sep;18(9):773-80
pubmed: 27593595
PLoS One. 2019 Jan 25;14(1):e0210579
pubmed: 30682046
Hepatobiliary Surg Nutr. 2014 Oct;3(5):238-46
pubmed: 25392835
AJR Am J Roentgenol. 2018 Sep;211(3):580-587
pubmed: 29995498
Liver Transpl. 2004 Feb;10(2 Suppl 1):S58-63
pubmed: 14762841
HPB (Oxford). 2015 Mar;17(3):272-7
pubmed: 25297934
Br J Surg. 2010 Aug;97(8):1260-8
pubmed: 20602507
World J Surg Oncol. 2011 Nov 24;9:154
pubmed: 22115124
Radiology. 2012 Jun;263(3):874-83
pubmed: 22623698
Updates Surg. 2020 Dec;72(4):925-938
pubmed: 32749596
Surgery. 2017 Jul;162(1):37-47
pubmed: 28365007
Hepatogastroenterology. 2012 May;59(115):782-4
pubmed: 22020904
Clin Colon Rectal Surg. 2005 Aug;18(3):215-23
pubmed: 20011304